Podophyllotoxin: History, Recent Advances and Future Prospects

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Drug Discovery

Background:

• Podophyllotoxin and its derivatives are broad-spectrum pharmacologically active compounds.
• Etoposide, a key derivative, is a frontline chemotherapy drug and is being explored for COVID-19 cytokine storm treatment.
• Naturally occurring compounds exhibit low bioavailability, systemic toxicity, and drug resistance, limiting clinical use.

Purpose of the Study:

• To review the exigency of innovation and research in the global R&D and pharmaceutical industry for podophyllotoxin and related compounds.
• To highlight the need for structure-optimization strategies to improve druggability.
• To explore alternative sourcing, such as microbial origins, for podophyllotoxin.

Main Methods:

• Literature review of recent scientific findings on podophyllotoxin and its derivatives.
• Analysis of market predictions and R&D trends in the pharmaceutical industry.
• Evaluation of challenges and opportunities in drug development and production.

Main Results:

• Existing podophyllotoxin compounds face significant limitations including poor bioavailability, toxicity, and resistance.
• Synthetic derivative production is not economically feasible, necessitating alternative strategies.
• Renewable sources, including microbial origins, present a potential avenue for podophyllotoxin production.
• Continuous research is vital for improving the druggability and therapeutic potential of these compounds.

Conclusions:

• Significant innovation and research are required globally to overcome the limitations of podophyllotoxin and its derivatives.
• Structure-optimization and exploration of novel, cost-effective production methods are essential for pharmaceutical advancement.
• The therapeutic potential of podophyllotoxin-based drugs necessitates dedicated R&D efforts to address current challenges.